Bayer is deepening its ties with Harvard and MIT's Broad Institute, delving into cardiovascular genomics in hopes of spotlighting new therapeutic approaches to deadly diseases.
Are two breakthrough cancer drugs better than one? Pharma giant Merck and Waltham, MA-based Syndax plan to find out in a Phase Ib/II study matching the tiny biotech's entinostat with Keytruda, Merck's big anti-PD-1 therapy newly approved for melanoma.
The developer of a novel drug delivery platform for nitric oxide just raised $50 million in a financing round led by Irish life science investment fund Malin.
Hutchison China MediTech has met the primary endpoint of progression-free survival in a Phase II clinical trial for its metastatic colorectal cancer candidate fruquintinib (HMPL-013), putting it one step closer to China approval.
Novartis, a leader among companies using the immune system to fight cancer, is betting up to $750 million on a promising therapeutic approach from Aduro Biotech, widening its arsenal of potential treatments.
Johnson & Johnson and Google have partnered to create new robotic-assisted surgical platforms. The deal is the latest example of Google working with a major life sciences company to make a significant technological advance.
South Korea's Green Cross said it has signed an agreement with Nanolek, a Russia biopharmaceutical company, to produce its biologics in a three-month-old facility said to be state-of-the-art.
Kapstone Medical has partnered with high-profile 3-D printer Materialise to launch a service specifically for medical device entrepreneurs.
A group of the world's leading drugmakers have joined the U.K.'s ambitious initiative to sequence the genomes of 100,000 Britons, mining the data with hopes of finding new pathways to treat cancer and rare diseases.
In a $31 million development agreement with Emergent BioSolutions announced Monday, the Department of Health and Human Services said it will fund Phase III development for NuThrax, Emergent's new anthrax vaccine that's already been funded through Phase I and II by the NIH and the Department of Defense.